AGC Biologics plans to construct a new manufacturing facility in Yokohama Japan.
The new facility, spanning four storeys and 20,000 square metres, will offer services in mammalian cell culture, messenger RNA, and cell therapy.
The facility will provide comprehensive services ranging from pre-clinical to commercial stages for mammalian-based protein biologics, cell therapies, and messenger RNA (mRNA) products.
The site will host numerous 2,000 L single-use bioreactors and multiple 4,000 L or larger reactors dedicated to mammalian cell culture services.
This new site forms a crucial component of the strategic growth plan aimed at enhancing high-quality pharmaceutical development and manufacturing services within the Asia region. Its design is specifically geared towards addressing the surging global requirements for biologics and advanced therapy medicinal products (ATMPs).
The facility is projected to commence operations in 2026.
Name AGC Biologics
Type New Construction
Budget US$350 bn(¥50bn)